Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer

Everett J. Moding, Yufei Liu, Barzin Y. Nabet, +24

Nature Cancer

Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition

Barzin Y. Nabet, Mohammad Shahrokh Esfahani, Everett J. Moding, +29

Cell

Immune EvasionAutoimmune DiseaseAllergyImmunologyTumor Immunity +9

<i>KEAP1/NFE2L2</i> Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition

Michael S. Binkley, Young-Jun Jeon, Monica Nesselbush, +28

Cancer Discovery

Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non–Small Cell Lung Cancer

Youngtae Jeong, Jessica A. Hellyer, Henning Stehr, +8

Clinical Cancer Research

ERBB2 -Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies

Jody C. Chuang, Henning Stehr, Ying Liang, +5

Journal of Thoracic Oncology

MedicineTargeted TherapiesCell BiologyCancer TreatmentCancer Genetics +3

Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC

Sarah Waliany, Han Zhu, Heather A. Wakelee, +6

Journal of Thoracic Oncology

Cardiovascular DiseaseMedicinePharmacologyPharmacovigilance AnalysisMetastatic Nsclc +7

Crosstalk between small-cell lung cancer cells and astrocytes mimics brain development to promote brain metastasis

Fangfei Qu, Wojciech Michno, Chioma J. Madubata, +18

Nature Cell Biology

EpendymaGliomaBrain DevelopmentMedicineBrain Metastasis +7

ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy

Millie Das, Jonathan W. Riess, Paul Frankel, +9

Lung Cancer

MedicinePathologyCancer GenomicsErcc1 ExpressionCancer Treatment +6

Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC

Jessica A. Hellyer, Jacqueline V. Aredo, Millie Das, +4

Journal of Thoracic Oncology

Consolidation DurvalumabMedicinePathologyCancer TreatmentCancer Genetics +4

Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer

Jessica A. Hellyer, Henning Stehr, Millie Das, +5

Lung Cancer

OncologyMedicinePathologyCancer GenomicsBronchial Neoplasm +5